Cost-Effectiveness of Thrombectomy With or Without Alteplase in Large Vessel Occlusion Stroke

BACKGROUND AND OBJECTIVES: In stroke patients directly admitted to thrombectomy-capable centers, the value of intravenous thrombolysis (IVT) with alteplase before thrombectomy is time dependent. While early IVT may improve outcomes, delayed IVT administration lowers the likelihood of benefit. To date, no previous cost-effectiveness study has considered onset-to-treatment time. This study evaluated the cost-effectiveness of intravenous (IV) alteplase plus thrombectomy vs thrombectomy alone in patients admitted directly to thrombectomy-capable centers across 16 countries, stratified by onset-to-IVT time. METHODS: A decision tree integrated with a Markov model estimated costs, quality-adjusted life years (QALYs), and incremental net monetary benefit (INMB) over 15 years. A willingness-to-pay threshold of one gross domestic product per capita was applied for each country. Effectiveness data were derived from individual patient data from 6 trials including patients with anterior circulation large-vessel occlusion eligible for both IVT and thrombectomy who presented directly to thrombectomy-capable centers. Costs were obtained from a literature review. Onset-to-IVT time was categorized as <140, 140-169, 170-199, and ≥200 minutes. One-way sensitivity and probabilistic sensitivity analyses were performed to check robustness of results. RESULTS: Ninety-day functional outcome distributions from 2,268 patients (median age 71 years; 44% female) were used to model cost-effectiveness in a hypothetical cohort of 10,000 patients. Without accounting for onset-to-IVT time, IV alteplase plus thrombectomy seemed cost-effective in 13 countries (INMB: $85-$3,618; 50-65% probability of cost-effectiveness) and not cost-effective in the United States, China, and Vietnam, with modest health gains (0.06-0.08 QALYs per patient). Time-stratified analyses revealed that IVT plus thrombectomy was cost-effective in 16 countries when onset-to-IVT time was <140 minutes (INMB: $615-$30,645; 82%-98% probability) and at 140-169 minutes (INMB: $86-$16,918; 51%-77% probability). However, IV alteplase plus thrombectomy was no longer cost-effective in 8 countries at 170-199 minutes. Universally, the INMB was negative for onset-to-IVT times exceeding 200 minutes. DISCUSSION: Cost-effectiveness of IV alteplase plus thrombectomy varies per country and onset-to-IVT time. IV alteplase plus thrombectomy is cost-effective when IVT can be administered within 170 minutes from symptom onset. Cost-effectiveness of IV alteplase plus thrombectomy diminishes progressively with longer onset-to-IVT times and becomes detrimental after 200 minutes.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2026-04-17
DOI
https://doi.org/10.1212/wnl.0000000000214866
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-Effectiveness of Thrombectomy With or Without Alteplase in Large Vessel Occlusion Stroke

Urs Fischer, Andrew Bivard, Lei Zhang, Ryuzaburo Kanazawa et al.
Neurology
Acute Ischemic Stroke Management
article

Cost-Effectiveness of Thrombectomy With or Without Alteplase in Large Vessel Occlusion Stroke

Urs Fischer, Andrew Bivard, Lei Zhang, Ryuzaburo Kanazawa, J Gralla, Maarten Uyttenboogaart, Natalie E. LeCouffe, Johannes Kaesmacher, Geert J. Lycklama, Keigo Shigeta, Maarten M.H. Lahr, Charles B.L.M. Majoie, Daan Nieboer, Daniel Strbian, Kilian M. Treurniet, 彭亚, Seiji Okubo, Toshiaki Otsuka, Yohanna Kusuma, Steven Bush, E. Buskens, Peter Mitchell, Conor Houlihan, Chrysanthi Papagiannaki, Tomas Dobrocky, Fabiano Cavalcante, Raul G. Nogueira, Zhong Rong Miao, Solène de Gaalon, Bo Hong, Leon A. Rinkel, Manon Kappelhof, C. Nguyen, Marnat Gaultier, Yohei Takayama, Wenhuo Chen, Hester F. Lingsma, J W Liu, Yvo Roos, Guangxian Nan, Igor Sibon, Zifu Li, Pengfei Yang, Hongxing Han, Anouk van Norden, Geoffrey Donnan, Margaux Lefebvre, Yongwei Zhang, Durk-Jouke van der Zee, Masafumi Morimoto, Thomas Meinel, Aad van der Lugt, Christophe Cognard, Shouchun Wang, Wenjie Zi, Sheng Liu, Qi Fang, Fengli Li, Xiaoxi Zhang, Yuki Kamiya, Hongjian Shen, Congguo Yin, Huy Thang Nguyen, Jiacheng Huang, Kentaro Suzuki, Xiaochuan Huo, Henry Ma, Jeannette Hofmeijer, Robert J. van Oostenbrugge, Qingwu Yang, Jiaxing Song, Omer Eker, Chenghua Xu, Stephen Davis, Kazumi Kimura, Bart J. Emmer, Vincent Costalat, Pengfei Xing, Eike Piechowiak, Yongxin Zhang, Masataka Takeuchi, Vu Dang Luu, for the IRIS collaborators, Romain Bourcier, Bernard Yan, Ping Zhang, Wim H. van Zwam, Jonathan M. Coutinho, Yuji Matsumaru, Diederik W.J. Dippel, Mikito Hayakawa, Bruce Campbell, Simon Jung, Liyong Zhang
article en

Abstract

BACKGROUND AND OBJECTIVES: In stroke patients directly admitted to thrombectomy-capable centers, the value of intravenous thrombolysis (IVT) with alteplase before thrombectomy is time dependent. While early IVT may improve outcomes, delayed IVT administration lowers the likelihood of benefit. To date, no previous cost-effectiveness study has considered onset-to-treatment time. This study evaluated the cost-effectiveness of intravenous (IV) alteplase plus thrombectomy vs thrombectomy alone in patients admitted directly to thrombectomy-capable centers across 16 countries, stratified by onset-to-IVT time. METHODS: A decision tree integrated with a Markov model estimated costs, quality-adjusted life years (QALYs), and incremental net monetary benefit (INMB) over 15 years. A willingness-to-pay threshold of one gross domestic product per capita was applied for each country. Effectiveness data were derived from individual patient data from 6 trials including patients with anterior circulation large-vessel occlusion eligible for both IVT and thrombectomy who presented directly to thrombectomy-capable centers. Costs were obtained from a literature review. Onset-to-IVT time was categorized as <140, 140-169, 170-199, and ≥200 minutes. One-way sensitivity and probabilistic sensitivity analyses were performed to check robustness of results. RESULTS: Ninety-day functional outcome distributions from 2,268 patients (median age 71 years; 44% female) were used to model cost-effectiveness in a hypothetical cohort of 10,000 patients. Without accounting for onset-to-IVT time, IV alteplase plus thrombectomy seemed cost-effective in 13 countries (INMB: $85-$3,618; 50-65% probability of cost-effectiveness) and not cost-effective in the United States, China, and Vietnam, with modest health gains (0.06-0.08 QALYs per patient). Time-stratified analyses revealed that IVT plus thrombectomy was cost-effective in 16 countries when onset-to-IVT time was <140 minutes (INMB: $615-$30,645; 82%-98% probability) and at 140-169 minutes (INMB: $86-$16,918; 51%-77% probability). However, IV alteplase plus thrombectomy was no longer cost-effective in 8 countries at 170-199 minutes. Universally, the INMB was negative for onset-to-IVT times exceeding 200 minutes. DISCUSSION: Cost-effectiveness of IV alteplase plus thrombectomy varies per country and onset-to-IVT time. IV alteplase plus thrombectomy is cost-effective when IVT can be administered within 170 minutes from symptom onset. Cost-effectiveness of IV alteplase plus thrombectomy diminishes progressively with longer onset-to-IVT times and becomes detrimental after 200 minutes.

NeurologyVol. 106(9)
The Royal Melbourne Hospital (AU), University Medical Center Groningen (NL), University of Shanghai for Science and Technology (CN), Deakin University (AU), Army Medical University (CN), The University of Melbourne (AU), University of Groningen (NL), Second Military Medical University (CN), Universitas Airlangga (ID), University Hospital of Bern (CH), Erasmus MC (NL), UPMC Health System (US), Changhai Hospital (CN), Xinqiao Hospital (CN), Hanoi University of Pharmacy (VN), Amsterdam University Medical Centers (NL), Melbourne Health (AU), Nippon Medical School (JP)
Openalex Percentile: Top 19%
Acute Ischemic Stroke Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.